Research

INTRODUCTION

The Metabolic Disorder Research Lab is dedicated to advancing the understanding of metabolic diseases, with a particular focus on the role of adipokines in obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). Adipokines, the bioactive molecules secreted by adipose tissue, play a crucial role in metabolic homeostasis, inflammation, and insulin sensitivity. Dysregulation of adipokine signaling has been implicated in the pathogenesis of metabolic disorders, making them a key target for therapeutic interventions.

Our research lab aims to uncover the molecular mechanisms by which adipokines influence metabolic dysfunction and contribute to disease progression. By integrating basic science with translational research, we strive to develop innovative strategies for early detection, prevention, and treatment of obesity-related metabolic diseases.

DESCRIPTION OF RESEARCH

Jones lab employs a multidisciplinary approach to investigate the complex interactions between adipokines, metabolism, and disease states. Our key research areas include:

1. Adipokine Regulation and Function

We explore how adipokines, such as adiponectin, leptin, resistin, and visfatin, regulate glucose and lipid metabolism. Our studies aim to elucidate the molecular pathways that govern adipokine secretion and their downstream effects on insulin sensitivity, inflammation, and hepatic lipid accumulation.

2. Adipokines in Obesity and Insulin Resistance

Obesity is a major risk factor for insulin resistance and type 2 diabetes. We investigate how adipose tissue dysfunction alters adipokine secretion, leading to impaired glucose homeostasis and chronic low-grade inflammation. Our work seeks to identify novel biomarkers and therapeutic targets to improve metabolic health in obese individuals.

3. Role of Adipokines in Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is a growing global health concern, often associated with obesity and metabolic syndrome. Our lab examines the role of adipokines in hepatic lipid accumulation, fibrosis, and inflammation. We aim to define the mechanisms linking adipose tissue dysfunction to liver pathology and identify potential adipokine-based therapies for NAFLD and its more severe form, non-alcoholic steatohepatitis (NASH).

4. Repurposing Approved Drugs to Target Adipokines

Given the complexity of metabolic disorders, repurposing existing FDA-approved drugs presents a promising strategy for accelerating treatment development. Our lab investigates how established medications—such as anti-diabetic agents, anti-inflammatory drugs, and lipid-lowering therapies—modulate adipokine signaling to improve metabolic outcomes. By leveraging existing pharmacological agents, we aim to identify novel uses for widely available drugs, reducing the time and cost associated with developing new therapies while improving patient outcomes in obesity, diabetes, and NAFLD.

5. Translational Research and Therapeutic Development

Our ultimate goal is to translate our findings into clinical applications. We collaborate with clinicians and pharmaceutical scientists to develop adipokine-targeted therapies, investigate potential pharmacological interventions, and assess the efficacy of lifestyle modifications in restoring adipokine balance and improving metabolic health.

Through cutting-edge research, collaboration, and innovation, the Metabolic Disorder Research Lab is committed to addressing the global burden of obesity-related metabolic diseases and paving the way for novel therapeutic strategies.